Reducing Asthma Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy: A randomised trial (RAACENO)
Reducing Asthma Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy: A randomised trial (RAACENO)
Background: Childhood asthma is a common condition. Currently there is no validated objective test which can be used to guide asthma treatment in children. This study tests the hypothesis that the addition of fractional exhaled nitric oxide (FENO) monitoring in addition to standard care reduces the number of exacerbations (or attacks) in children with asthma. Methods: This is a multi-centre, randomised controlled study. Children will be included of age 6-16 years who have a diagnosis of asthma, currently use inhaled corticosteroids (ICSs) and have had an exacerbation in the previous 12 months. Exclusion criteria include being unable to provide FENO measurement at baseline assessment, having another chronic respiratory condition and being currently treated with maintenance oral steroids. Participants will be recruited in both primary and secondary care settings and will be randomised to either receive asthma treatment guided by FENO plus symptoms (FENO group) or asthma treatment guided by symptoms only (standard care group). Within the FENO group, different treatment decisions will be made dependent on changes in FENO. Participants will attend assessments 3, 6, 9 and 12 months post randomisation. The primary outcome is asthma exacerbation requiring prescription and/or use of an oral corticosteroid over 12 months as recorded by the participant/parent or in general practitioner records. Secondary outcomes include time to first attack, number of attacks, asthma control score and quality of life. Adherence to ICS treatment is objectively measured by an electronic logging device. Participants are invited to participate in a "phenotyping" assessment where skin prick reactivity and bronchodilator response are determined and a saliva sample is collected for DNA extraction. Qualitative interviews will be held with participants and research nurses. A health economic evaluation will take place. Discussion: This study will evaluate whether FENO can provide an objective index to guide and stratify asthma treatment in children. Trial registration: ISRCTN, ISRCTN67875351. Registered on 12 April 2017. Prospectively registered.
Turner, S.
f901f3b7-f5fd-48ad-8e0f-b870260ce5cd
Cotton, S. C.
23842542-535b-414c-92d7-5032a895b8de
Emele, C. D.
4bdc8e3b-9dcc-45b4-a575-c96235563f7d
Thomas, R.
ea61b554-74ea-4593-94af-6b4c2536005b
Fielding, S.
7b9ebc62-a1f9-41e7-80a3-584fc9d8e567
Gaillard, E. A.
331211c9-e97f-407c-b107-4e0461f29a6f
De Jongste, J. C.
3902188e-c058-4f21-a024-148fa9c3c346
Morgan, H.
d7634782-b449-49ff-b477-d8eecf30ea3e
Neilson, A. R.
7f0727ce-89c8-4c00-9942-6fdc8e6da13e
Norrie, J.
d648d104-39a0-481f-af0f-9a7209d50fb5
Pijnenburg, M.
2fc055f2-ddbc-4bb7-801b-45ac9d8663a9
Price, D.
8460fd97-a852-477b-a49d-d62b4dbb9939
Thomas, M.
997c78e0-3849-4ce8-b1bc-86ebbdee3953
4 October 2019
Turner, S.
f901f3b7-f5fd-48ad-8e0f-b870260ce5cd
Cotton, S. C.
23842542-535b-414c-92d7-5032a895b8de
Emele, C. D.
4bdc8e3b-9dcc-45b4-a575-c96235563f7d
Thomas, R.
ea61b554-74ea-4593-94af-6b4c2536005b
Fielding, S.
7b9ebc62-a1f9-41e7-80a3-584fc9d8e567
Gaillard, E. A.
331211c9-e97f-407c-b107-4e0461f29a6f
De Jongste, J. C.
3902188e-c058-4f21-a024-148fa9c3c346
Morgan, H.
d7634782-b449-49ff-b477-d8eecf30ea3e
Neilson, A. R.
7f0727ce-89c8-4c00-9942-6fdc8e6da13e
Norrie, J.
d648d104-39a0-481f-af0f-9a7209d50fb5
Pijnenburg, M.
2fc055f2-ddbc-4bb7-801b-45ac9d8663a9
Price, D.
8460fd97-a852-477b-a49d-d62b4dbb9939
Thomas, M.
997c78e0-3849-4ce8-b1bc-86ebbdee3953
Turner, S., Cotton, S. C., Emele, C. D., Thomas, R., Fielding, S., Gaillard, E. A., De Jongste, J. C., Morgan, H., Neilson, A. R., Norrie, J., Pijnenburg, M., Price, D. and Thomas, M.
(2019)
Reducing Asthma Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy: A randomised trial (RAACENO).
Trials, 20 (1), [573].
(doi:10.1186/s13063-019-3500-7).
Abstract
Background: Childhood asthma is a common condition. Currently there is no validated objective test which can be used to guide asthma treatment in children. This study tests the hypothesis that the addition of fractional exhaled nitric oxide (FENO) monitoring in addition to standard care reduces the number of exacerbations (or attacks) in children with asthma. Methods: This is a multi-centre, randomised controlled study. Children will be included of age 6-16 years who have a diagnosis of asthma, currently use inhaled corticosteroids (ICSs) and have had an exacerbation in the previous 12 months. Exclusion criteria include being unable to provide FENO measurement at baseline assessment, having another chronic respiratory condition and being currently treated with maintenance oral steroids. Participants will be recruited in both primary and secondary care settings and will be randomised to either receive asthma treatment guided by FENO plus symptoms (FENO group) or asthma treatment guided by symptoms only (standard care group). Within the FENO group, different treatment decisions will be made dependent on changes in FENO. Participants will attend assessments 3, 6, 9 and 12 months post randomisation. The primary outcome is asthma exacerbation requiring prescription and/or use of an oral corticosteroid over 12 months as recorded by the participant/parent or in general practitioner records. Secondary outcomes include time to first attack, number of attacks, asthma control score and quality of life. Adherence to ICS treatment is objectively measured by an electronic logging device. Participants are invited to participate in a "phenotyping" assessment where skin prick reactivity and bronchodilator response are determined and a saliva sample is collected for DNA extraction. Qualitative interviews will be held with participants and research nurses. A health economic evaluation will take place. Discussion: This study will evaluate whether FENO can provide an objective index to guide and stratify asthma treatment in children. Trial registration: ISRCTN, ISRCTN67875351. Registered on 12 April 2017. Prospectively registered.
Text
s13063-019-3500-7
- Version of Record
More information
Accepted/In Press date: 5 June 2019
Published date: 4 October 2019
Identifiers
Local EPrints ID: 435107
URI: http://eprints.soton.ac.uk/id/eprint/435107
ISSN: 1745-6215
PURE UUID: 3005e5a6-1da2-4817-a746-59ee4c702f75
Catalogue record
Date deposited: 23 Oct 2019 16:30
Last modified: 16 Mar 2024 04:49
Export record
Altmetrics
Contributors
Author:
S. Turner
Author:
S. C. Cotton
Author:
C. D. Emele
Author:
R. Thomas
Author:
S. Fielding
Author:
E. A. Gaillard
Author:
J. C. De Jongste
Author:
H. Morgan
Author:
A. R. Neilson
Author:
J. Norrie
Author:
M. Pijnenburg
Author:
D. Price
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics